Dear group

Please help me with this document

regards


Allergy Asthma Proc.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=Randomized+controlled+trial+of+desloratadine+for+persistent+allergic+rhinitis%3A+correlations+between+symptom+improvement+and+quality+of+life.#>
2013
May-Jun;34(3):274-82. doi: 10.2500/aap.2013.34.3668.
Randomized controlled trial of desloratadine for persistent allergic
rhinitis: correlations between symptomimprovement and quality of life.
Bousquet J
<http://www.ncbi.nlm.nih.gov/pubmed/?term=Bousquet%20J%5BAuthor%5D&cauthor=true&cauthor_uid=23676577>
1, Zuberbier T
<http://www.ncbi.nlm.nih.gov/pubmed/?term=Zuberbier%20T%5BAuthor%5D&cauthor=true&cauthor_uid=23676577>
, Canonica GW
<http://www.ncbi.nlm.nih.gov/pubmed/?term=Canonica%20GW%5BAuthor%5D&cauthor=true&cauthor_uid=23676577>
, Fokkens WJ
<http://www.ncbi.nlm.nih.gov/pubmed/?term=Fokkens%20WJ%5BAuthor%5D&cauthor=true&cauthor_uid=23676577>
, Gopalan G
<http://www.ncbi.nlm.nih.gov/pubmed/?term=Gopalan%20G%5BAuthor%5D&cauthor=true&cauthor_uid=23676577>
, Shekar T
<http://www.ncbi.nlm.nih.gov/pubmed/?term=Shekar%20T%5BAuthor%5D&cauthor=true&cauthor_uid=23676577>
.
Author information
<http://www.ncbi.nlm.nih.gov/pubmed/?term=Randomized+controlled+trial+of+desloratadine+for+persistent+allergic+rhinitis%3A+correlations+between+symptom+improvement+and+quality+of+life.#>
Abstract

Allergic rhinitis (AR) symptoms can impart emotional, quality of life (QOL),
and work productivity burdens, especially in persistent AR (PER).
Desloratadine, an H1-receptor antagonist, has been shown to be effective
against nasal and nonnasal AR symptoms and to improve QOL. Exploratory
analyses were conducted to evaluate whether desloratadine-mediated symptom
improvement correlated with improvements in QOL and productivity. The
Aerius Control: Clinical and Evaluative Profile of Treatment 2
(NCT00405964) study was a 12-week, multinational, randomized, placebo-
controlled prospective study of once-daily desloratadine at 5 mg in
subjects with moderate-to-severe PER. Assessments included twice-daily
symptom severity ratings (0 = none to 3 = severe; total and individual
symptoms), sleep interference (morning [A.M.]), interference with
activities of daily living (ADL; evening [P.M.]), the Rhinoconjunctivitis
Quality of Life Questionnaire-Standardized version (baseline and days 29
and 85), and the Work Productivity and Activity Impairment-Allergy-Specific
questionnaire (baseline and weekly). Pearson product-moment correlation
statistics (r) were determined to assess correlations between symptom score
improvements and QOL factors. All desloratadine-treated patients (n = 360)
were included in this exploratory analysis. In the desloratadine-treated
patients, all correlations tested were positive (all p < 0.0001). The
highest coefficients were seen for the correlations between A.M./P.M. PRIOR
total five-symptom score and interference with ADL (r = 0.72) and between
A.M. NOW congestion and ADL interference (r = 0.69). Continuous daily
treatment of moderate-to-severe PER with desloratadine at 5 mg/day
significantly improved symptoms, which correlated positively, albeit
moderately, with QOL benefits and reversal of functional impairments caused
by PER.
PMID: 23676577 [PubMed - indexed for MEDLINE]